StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)

Close on Nov 17, 2026Market cap $1.57BP/E –Yield –

Vir Biotechnology price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Vir Biotechnology's price to sales ratio was 7.3× on Nov 11, 2026, against 52.9× a year earlier. Over the last 5 years it ranged from 1.2× to 61.3×, with a median of 12.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.3×−42.4
2025Dec 31, 202549.7×+37.0
2024Dec 31, 202412.8×+1.4
2023Dec 29, 202311.4×+10.0
2022Dec 30, 20221.4×−17.8
2021Dec 31, 202119.3×−25.7
2020Dec 31, 202045.0×+30.6
2019Dec 31, 201914.4×–

More Vir Biotechnology figures

See a number that looks wrong?